Press

Spanish biotechs raise 228 million euros in private financing in 2023

15/05/2024

Financing

• During the AseBio Investor Day, held on May 15th in San Sebastián, AseBio has revealed data on private financing collected in the AseBio 2023 Report.
• The AseBio 2023 Report, a leading publication in the Spanish biotechnology sector, will be presented on June 12th at the Rafael del Pino Foundation in Madrid.
• In its fifth edition, the AseBio Investor Day 2024 has brought together nearly 280 attendees from over 180 entities from 19 countries, including 70 investors from more than 55 investment firms.
  
   

AseBio

The synergy between biotechnology and immunology catalyzes the development of more effective vaccines and personalized immunological therapies: a new horizon for addressing autoimmune diseases, cancer, and infectious pathologies

29/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies

• Biotechnology has achieved significant advances in diagnosis and precision therapies, the production of biotechnological drugs, and the treatment and understanding of infectious, autoimmune, and cancer diseases, among other areas.
• CAR-T therapies or monoclonal antibodies, two major advances in recent years in the field of immunology, are examples of the great potential of biotechnological innovation.
   

AseBio

Biotechnology and DNA: The duo paving the way for the era of customization in health and agriculture

25/04/2024

Healthcare · Access to innovation · Biosimilars · Personalized medicine · Advanced therapies · Gene editing

• Next-generation DNA sequencing has a significant impact on personalized medicine, genomic research, and the identification of genetic diseases.
• Genomic medicine is emerging as a central pillar of the future of healthcare, as the ability to personalize treatments based on each individual's genetics is transforming our approach to health.
• Genome editing has the potential to address real challenges for farmers and the planet, such as developing crops more resistant to diseases and the effects of climate change.

AseBio

AseBio launches the Food Innovation Working Group to boost the biotechnological potential of the Spanish agri-food sector

17/04/2024

Agrifood · Food & feed · Agriculture · Animal health

• The Spanish agri-food sector has undeniable strategic value for the national economy due to its impact on GDP: Spain ranks as the eighth global agri-food power.
• Within AseBio, over 25% of our members work in the agri-food sector, with presence across the entire value chain: from R&D phases to industrial stage.
• This group focuses its objectives on highlighting Spanish food innovation and Food tech, as well as driving food innovation to achieve recognition of new types of nutrients for both human and animal consumption.
  
   

AseBio

The "yes" from the European Parliament to the reform of pharmaceutical legislation jeopardizes biotechnological innovation if improvements are not introduced

12/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies · Antibiotic resistance

• We consider that improvements have been made regarding the original proposal, but these continue to be insufficient for the protection, development, and promotion of biotechnological innovation in Europe.
• Biotechnology has radically transformed the discovery of new drugs: 68% of the drugs currently in development globally are biotechnological.
• The GPL is not aligned with the European Commission, which has identified biotechnology as one of the key 'deep tech' areas for the future of the European Union and its strategic autonomy.
  
   

AseBio

Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative disease

11/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies

• Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000 individuals.
• Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating symptoms once the diagnosis has been made.
• Biotechnology seeks solutions such as the project "Development of new drugs for the treatment of Parkinson's through AI and massive screening of compounds," in which Celtarys Research, ZeClinics, and the Biofarma group of the University of Santiago de Compostela participate, coordinated by AseBio.
  
   

AseBio

Biotechnology lays the groundwork for the present and future of healthcare and drives the One Health approach

07/04/2024

Healthcare · Drug discovery · Rare diseases · Personalized medicine · Advanced therapies · Antibiotic resistance · Climate change · Agrifood · Agriculture · Animal health

• AseBio's health pipeline includes 130 molecules for 150 indications being researched by 40 national companies, with oncology as the majority area.
• Spain stands out as one of the leading countries in advanced therapies: 47 AseBio member entities work in this area, and more than 30 have capabilities for their complete development.
• 43 AseBio member entities take direct actions aimed at combating antibiotic resistance through various capacities.
   

AseBio

Sustainable agriculture, new food sources, protection against infectious diseases or waste reuse: this is how biotechnology contributes to the sustainability of the planet

25/03/2024

Healthcare · Biosimilars · Rare diseases · Climate change · Agrifood · Food & feed · Agriculture

• Humanity is at a critical moment for its future, with the need to promote more sustainable economic models that respond to social and environmental challenges.
• Biotechnology provides solutions through plant genetic engineering, the revaluation of food industry by-products, new food sources and biofuels, among others. 
   

AseBio

AseBio expresses concern about Spain's ability to certify medical devices

21/03/2024

Healthcare · Drug discovery · Industrial biotechnology

• The current scenario shows a worrying bottleneck with a detriment to innovative biotech products, indefinitely delaying their access to the market.
• Currently in Europe only 12 conformity assessment bodies have managed to become notified bodies with the regulation (EU) 2017/746.
• In the case of Spain, we have the National Certification Center for Medical Devices as a notified body for medical devices under Regulation (EU) 2017/745, but it has not been designated for Regulation (EU) 2017/746 for IVD products.

 

AseBio